Ligand Pharmaceuticals (LGND) logo

Ligand Pharmaceuticals (LGND) stock

Medicine technologies , market cap $5.7B

$286.85
-0.03%

Quality Score
8
Average
In its industry
#40of 273
Checks firing
2of 14
Choppy
From 52-week high
-12.2%
under its best in a year

LGND's Quality Score was unchanged on Fri, Nov 20, at 8.

Follow LGND's news. Pro members can get an alert when Ligand Pharmaceuticals files news, and see its trials, share raises, and its CEO's filings.

Get an alert when LGND files newsSee it live, free until Tuesday morning. No account. No card.One stock in full, free. No account.$1 for a first month of Pro. Then $39 a month. Then keep going with a free account.Then $1 for a first month of Pro.Then 7 days of Pro free, with a card.

We do the work for you. Every stock is scored and ranked, every 15 seconds while the market is open. Here it's 15 minutes behind. Pro members see it live.

Next2H 2026“…remains on track to submit the remaining modules and complete the NDA submission in the second half of 2026…”Filing with regulators · SEC filing · Aug 6

Why LGND beats the market

Up 394% over three years while the S&P 500 rose 58%.

  • Its operating margin went from 1.5% in fiscal 2022 to 15.3% in fiscal 2025; its 2 peers' median rose 6.0 points.

Sources: Price history, Nov 20, 2026; Annual reports, Dec 31, 2025; Peers' annual reports, Nov 20, 2026

1 more reason, free with an account →See every reason on LGND →3 more reasons why LGND beats the market, from its filings, with the company's words, the timeline, and its peers, for Pro members.

Key facts on LGND

Key facts on LGND
The chartStronger than 90% of stocks above a rising 200-day average
Latest filing10-Q, Oct 30 Filed its quarterly report (10-Q) for the quarter to Sep 30, 2026

What's next

Expected to report Thu Feb 25, before the open

After its last 4 reports it closed -2.1% on average, higher 1 of 4 times.

LGND catalysts

Coming up

4 more coming up and 45 past catalysts since 2019, with sizes and sources, for Pro members.

What's next for LGND

Next step the company has named

2H 2026“Palvella remains on track to submit the remaining modules and complete the NDA submission in the second half of 2026.”Filing with regulators · SEC filing · Aug 6

What it means: a filing asks regulators to approve a drug for sale. Once it is complete and accepted, the FDA sets a decision date, and we show it here.

For Pro members: 4 more milestones and 42 filings.

Dilution on the horizon

  • Shelf registration (S-3ASR, filed Feb 27, 2026)
  • At-the-market share sales program (S-3ASR, filed Feb 27, 2026)

For Pro members: the amounts, and the share count against a year ago.

Insiders

Director Martine Zimmermann sold 2,000 shares on Nov 12. 30 more insider trades this year.

From Form 4: open-market buys and sales only.

For Pro members: every trade, and Todd Davis’s 17 filings and quotes.

Get an alert when LGND files newsA free account. No card.Pro: $1 first month.Pro, 7 days free with a card.

See every upcoming FDA date →

FDA dates in the next 60 days

Decision dates and advisory committee meetings the companies have announced in their filings, soonest first and small companies first.

DateStockDrug

12 more FDA dates and 98 trial data dates in the next 60 days, each on the FDA calendar. Pro members see whether each company's cash lasts past its date, with an optional alert before it. See all 144 dates, ranked →See all 144 dates, ranked →Start Pro

Why LGND scores 8

Averagefor quality, not price, 2 of 14 chart checks firingWhat the Quality Score means

Well below its recent run. LGND scores 8 today, against a median of 15 over its last 20 recorded sessions.

  • +3Long-term trend above a rising 200-⁠day average, near its 52-⁠week high
  • −1Insider trades Martine Zimmermann (Director) sold $636K on Nov 12 near the 52-⁠week high. $2.7M sold by 2 sellers in three months
  • Chart checks adds
  • Profit addsRead on the last four quarters against the four before, or the last full year where no quarters are filed.
  • Growth addsSales and margins against a year earlier: up to +3 for fast growth and widening margins, down to -2 when both shrink.
  • Persistence adds

No effect today: Run-up, Size, Dilution, Volatility, Cash flow, and News.

What every line is worth, and the reason behind it, on LGND and every other stock.Get in free →See the top 3 →Start Pro

Price, score, chart checks, and the industry rank are from a snapshot taken at 8:34 PM ET, at least 15 minutes behind. How we rank stocks.

Tested. Our top-scored stocks returned 2.2x the average stock over the next month. Reconstructed after the fact; recorded live since Sep 9, 2026. How we tested it

Alert me when LGND's Quality Score turns up

A free account. No card.Pro: $1 first month.Pro, 7 days free with a card.

How LGND ranks in Biotech

LGND is #40 of 273 by Quality Score.

How LGND ranks in Biotech
RankStockQuality Score
40Ligand Pharmaceuticals (LGND) logoLGNDLigand Pharmaceuticals8

More in Biotech

When does LGND report earnings, and what happens after?

Expected to report Thu Feb 25, before the open (in 96 days).

What an earnings report is: every 3 months, a company tells everyone how much it sold and earned. We read the figures, the outlook, and how the stock moved after.

What LGND reported on Oct 29, 2026

The quarter

A loss of $1.43 a share, from a profit of $5.68.

“Royalties accounted for 89% of total revenues and income in the quarter, with growth driven by the newly acquired XOMA assets and continued momentum across Ligand’s key commercial portfolio, including Travere Therapeutics’ Filspari and Merck’s Ohtuvayre.”

The quarter that ended Sep 30, from the company's press release

The press releaseThe filing on EDGAR

Where the sales came from

Where the quarter's sales came from
LineQ3
2026
Q2
2026
Q3
2025
By product
Royaltyup 51%$70.3M32%$48M27%$46.6M14%

Each quarter's sales and their share of its total. Figures as filed (SEC filing, Oct 30)

21 more lines, for Pro members.

The outlook

The outlook the company gave, by period
MeasureFigure
2026 full year
Adjusted earnings per diluted share$9.50 to $9.75raised

Figures as filed (SEC filing, Oct 29)

2 more outlook lines, for Pro members.

In the company's words

  • “The decreases were primarily attributable to the $24.5 million of Pelthos out-license income recognized in the prior-year period (see Pelthos note below) and higher general and administrative expense excluding share-based compensation and transaction and integration costs, partially offset by the 51% increase in royalty revenue.”

From its results filing (SEC filing · Oct 29)

The numbers

Market value
$5.7B
today
Sales
$254M
up 1% on the year
Free cash flow
$90.6M
last 12 months

Sales grew 10% a year over 5 years, fiscal 2020 to 2025.

Its share count grew 3.8% a year over 5 years.

5 more figures, for Pro members.

No analyst estimates on Breakaway: every figure here is filed.

The whole report on LGND: every line of its sales, every outlook beside the one it replaced, and the company's words, for Pro members.

Close after the report, last 3

-9.6%-0.8%-0.5%
May 7Aug 6Oct 29
ReportedGapReaction5
days
Oct 29, 2026Before open-1.1%-0.5%-0.8%
Aug 6, 2026Before open+1.2%-0.8%-3.1%
May 7, 2026Before open-11.8%-9.6%-4.9%

LGND closed higher after 1 of its last 4 reports.

All 4 reports, and LGND's Quality Score going into each

LGND sales and profit by year

Sales and profit by year

Sales grew in four of the last seven years, to $268M in 2025. It turned a profit in 2025 after a loss in 2024.

LGND has 2 of 14 chart checks firing

Volume1 of 3 shown
Tight range1 of 3 shown
Buying1 of 3 shown
The other 10 checks on LGND, and all 14 on every stock.Get in free →See the top 3 →Start Pro

LGND RSI on Nov 20: 38.8, below its 50-day, above its 200-day

Not scored

RSI 38.8, MACD below signal, below its 50-day, above its 200-day. Not scored.

The deep dive on LGND

  • What it does and how it makes money6 findingsRoyalties made up 60% of its revenue in fiscal 2025 ($161M of $268M), against 65% in fiscal 2024; contract revenue and income 25% and Material Sales, Captisol 15%.SEC filing · Feb 27, 2026"We maintain a broad global patent portfolio for Captisol with the latest expiration date in 2033." (10-K for fiscal 2025)SEC filing · Feb 27, 2026
  • Where it stands3 findingsFor Pro members3 findings on where LGND stands: its cash, debt, and share count, for Pro members
  • What changed in its filings10 findings"On August 22, 2024, CyDex Pharmaceuticals, Inc. filed a Verified Complaint in the Delaware Court of Chancery against Bexson Biomedical …" (10-Q for the quarter to Sep 30, 2026)SEC filing · Oct 30, 2026A new heading in its "Risk Factors" this year: "The royalty market may not grow at the same rate as it has in the past, or at all, and we may not be able to acquire sufficient royalties to sustain the growth of our business." (10-K for fiscal 2025; not in fiscal 2024's)SEC filing · Feb 27, 2026, against the one of Feb 28, 2025One partner made up 22% of its revenue in fiscal 2025, down from 23% in fiscal 2024; another made up 17%, up from 12% in fiscal 2024.SEC filing · Feb 27, 2026
  • Who holds and trades it2 findingsFor Pro members2 findings on who holds and trades LGND, for Pro members

16 more findings on LGND, each with its source, for Pro members.

LGND share count over time

Shares: 2.0% more than a year ago (to Sep 30).

Shares of LGND outstanding, as filed
Shares
outstanding
As
of
20MOct 27, 2026
19.9MAug 4, 2026
20MMay 5, 2026
19.9MFeb 24, 2026
Offerings, shelves, and splits of LGND, from its filings
From its
filings
Filed
Registered shares for a later sale (S-3ASR)Feb 27, 2026

LGND insider trades

5 insiders sold $9.4M across 25 filings in the last 6 months. No open-⁠market buys on record. The newest:

SellMartine Zimmermann$636KDirectorat $318.17 on Nov 12, filed Nov 16

All 25 insider filings on LGND from the last six months, for Pro members.

All LGND insider trades

LGND trades by Congress and the executive branch

2 trades disclosed in the last six months. The newest:

SellDonald Trump$15K to $50KPresident (R)traded May 15, disclosed Jul 1(47 days later)
All 2 trades on LGND disclosed by Congress and the executive branch, for Pro members.Get in free →See the top 3 →Start Pro

See what Congress is buying across the market

LGND's officers and directors

Officers and directors with a Form 4 in the last 12 months.

5 more officers and directors file at LGND.

See insider trades by person

Which ETFs hold LGND?

In ETFs: LGND is under 0.1% of VTI, the most of the 24 funds Breakaway covers, by their holdings as filed for Jun 30, 2026.

About Ligand Pharmaceuticals

Ligand Pharmaceuticals Inc is a biopharmaceutical company focused on developing and acquiring technologies that aid in creating medicine. The company has partnerships and license agreements with various pharmaceutical and biotechnology companies. Ligand's business model is based on drug discovery, early-stage drug development, product reformulation, and partnerships. The company's revenue consists of three primary elements: royalties from commercialized products, license and milestone payments, and sale of its trademarked Captisol material.

47 employeesSan Diego, CAligand.com

What Ligand Pharmaceuticals says it competes with

“Some of the drugs we and our licensees and partners are developing may compete with existing therapies or other drugs in development by other companies.”

From its annual report, SEC filing · Feb 27, 2026

Here is what Pro members see.

  • The same page for Pro members, on Microsoft

    Its Quality Score and rank, the line that drives it, and the live price.

  • The full chart

    A year of candles to start, out to the whole history, with insider trades marked and the Quality Score under the price.

  • Every line of the score

    Price action, the company, and signals, each with its points, on LGND and every other stock.

  • FDA dates, counted down

    Each date in the company's words, its cash against the date, and an optional alert before it.

  • CEOs buying their own stock

    Every CEO buy, biggest names first. Sort, filter, save the list, and set optional alerts.

  • Congress trades

    A member's trades, newest first, each with its amount. Sort and filter the whole list.

  • 14 chart checks, read for you

    The ones firing on the stock, each in plain words, its rule a tap away.

  • Earnings, week by week

    Who reports each day, and how each stock took its last four reports.

  • The market map

    Every stock a box, colored by its Quality Score.

  • Themes, ranked live

    Each theme's stocks ranked by Quality Score, live. Here, AI chips.

  • The top 10, every day

    The ten highest Quality Scores at each close, kept day by day, week by week.

  • Optional alerts, your way

    Pick a stock, a score, a price, a filing, or a whole scan. It tells you by push or email.

  • Your watchlist, scored

    Your stocks by Quality Score, today's move, or name.

  • On your phone and your laptop

    The same account and watchlist on both, each laid out for its screen.

  • Prices refresh every 2.5 seconds during market hours.
  • Optional alerts by push, email, or the bell.
  • Add it to your Home Screen and it opens like an app.

Pro members see every line of every stock's score.

  • What would move LGND's score: 5 things
  • 5 more filings explained, a plain line each
  • Real-⁠time prices, no delay
BreakawayJun 8Gilbert Cisneros bought LGND$1K to $15K, disclosed Jun 8

Alerts are optional.

See it live, free until Tuesday morning. No account. No card.One stock in full, free. No account.$1 for a first month of Pro. Then $39 a month. Then keep going with a free account.Then $1 for a first month of Pro.Then 7 days of Pro free, with a card.

Straight AnswersStraight Answers

As of Nov 21, 2026: LGND's Quality Score is 8 (Average), #40 of 273 in Biotech. Insiders sold $9.4M in the last 6 months (Form 4).

What does LGND's Quality Score say?

LGND scores 8 today, which Breakaway calls Average. It is #40 of 273 in Biotech by Quality Score, with 2 of 14 chart checks firing. Up 394% over three years while the S&P 500 rose 58%. Breakaway does not say whether to buy any stock: the score does not know your situation, and it is not a recommendation to buy or sell anything. Please do your own research.

What is LGND's Quality Score?

LGND scores 8 today, which Breakaway calls Average (6 to 10). That is #40 of 273 in Biotech by Quality Score. The score adds up the chart checks, the trend, the company's filed sales, its profits, the news, insider trades, and Congress trades. The section above lists the lines behind LGND's 8.

Are insiders buying LGND?

5 insiders sold $9.4M across 25 filings in the last 6 months. No open-⁠market buys on record. The newest is Martine Zimmermann, Director, who sold $636K on Nov 12. Every filing, with the scored weight, for Pro members.

Are the prices delayed?

Only on the public pages, which run at least 15 minutes behind. Pro members, and anyone on a guest pass, see real-time prices: the scanner refreshes every 15 seconds, and your watchlist every few seconds, pre-market and after hours included.

Only on the public pages, which run at least 15 minutes behind. Pro members see real-time prices: the scanner refreshes every 15 seconds, and your watchlist every few seconds, pre-market and after hours included. The one stock you open in full is live too.

Every US stock, ranked live.

Insider and Congress trades, the chart, and the financials, in one score.

See all 3,170 stocks rankedSee all 3,170 stocks rankedStart Pro

See it live, free until Tuesday morning. No account. No card.One stock in full, free. No account.$1 for a first month of Pro. Then $39 a month. Then keep going with a free account.Then $1 for a first month of Pro.Then 7 days of Pro free, with a card.

What's next for Ligand Pharmaceuticals: from its SEC filings and ClinicalTrials.gov, the company's words, the registry's dates, and arithmetic, not a forecast. Companies often miss the dates they set.

The moves after past earnings reports are past behavior, not a forecast.

The price, the score, the chart checks and readings, and the industry rank on this page are delayed at least 15 minutes.

Our top-scored stocks' record: Oct 2021 to Sep 2026, before costs. Recorded live since Sep 9, 2026.

Breakaway publishes impersonal securities research and analytical tools: one formula, the same score for everyone. It is not personalized investment advice, and nothing here is a recommendation to buy or sell any security.

Market data from a licensed vendor. The age of every quote is shown on the page.

This browser is too old to show this page right. Update it, or open this page in Safari or Chrome.